Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

NCT04622865 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV 2
COVID-19
Coronavirus Disease 2019

Interventions

DRUG: Masitinib
DRUG: Isoquercetin
DRUG: Best Supportive Care

Sponsor

AB Science